Nearly all adults with neuromyelitis optica spectrum disorder (NMOSD) experience headaches, especially migraines, a single-center study in Iran suggests. The presence of abnormalities in brain MRI scans and the use of the immunosuppressive therapy rituximab were each linked to an increased chance of new or worsening headaches after a…
News
A six-week psychotherapy program, tailored specifically for people with neuromyelitis optica spectrum disorder (NMOSD) and delivered via telehealth, helped to ease anxiety and depression in adults with these conditions — with benefits lasting up to three months after treatment. These are the findings of a U.S. pilot clinical trial…
Ultomiris (ravulizumab), an approved infusion therapy for adults with neuromyelitis optica spectrum disorder (NMOSD), is closer to being eligible for reimbursement under public drug plans in Canada, according to its developer, Alexion, AstraZeneca Rare Disease. The company signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA).
People diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who lose their jobs or cut back on their hours likely contend with vision loss, worsening pain, the use of walking aids, and frequent fatigue or depressed mood, an international study reports. “Developing a robust set of disability guidelines to protect…
Using noninvasive eye scans may help clinicians to determine if patients — particularly those in early disease stages — have neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), both immune system disorders. That’s according to a review of published studies that together reveal that people with NMOSD…
The infusion therapy Ultomiris (ravulizumab-cwvz) safely and effectively reduces the risk of a relapse in complex cases of neuromyelitis optica spectrum disorder (NMOSD) and may be combined with rituximab for short periods, a case series study shows. For four NMOSD patients at a hospital in Fujiyoshida, Japan, Ultomiris…
Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
A new artificial intelligence (AI) model that analyzes images of the eye can help accurately identify neuromyelitis optica spectrum disorder (NMOSD), a study shows. The model outperformed specialists when relying solely on eye images. When clinical data such as MRI scans and antibody tests were provided, the model’s accuracy…
Most people with neuromyelitis optica spectrum disorder (NMOSD) have impaired sleep quality and architecture — an individual’s cyclical sleep pattern, involving different stages — relative to healthy people, according to a new study from researchers in India. NMOSD patients were also found to have reductions in the volume of…
People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases, or those affecting the joints, muscles, or connective tissue, a South Korean study found. Connective tissue provides support, connection, and binding for tissues and organs. The findings align with a…
Recent Posts
- NMOSD: A full-time job with no pay, no vacation time, and lousy benefits
- Use of umbilical cord cells shown to safely cut relapses in NMOSD in trial
- The 3-inch high heels that were an act of rebellion against NMOSD
- 2 NMOSD drugs show equal power at preventing disease relapses
- Confessions of the kind of NMOSD patient doctors warn their interns about